Federal contract award
75N93018C00025
IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $11.3M |
| Current contract value | $11.3M |
| Potential contract value / ceiling | $18.8M |
| Start date | Sep 21, 2018 |
| Current end date | Aug 31, 2026 |
| Potential end date | Aug 31, 2026 |
| Latest award activity | Dec 10, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 20 of 20 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Dec 10, 2025 | P00019 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Jul 1, 2025 | P00018 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Apr 18, 2025 | P00017 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Mar 6, 2025 | P00016 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Dec 13, 2024 | P00015 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Aug 5, 2024 | P00014 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Mar 20, 2024 | P00013 | $1.3M | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Jan 31, 2024 | P00012 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Jun 30, 2023 | P00011 | $-423 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Mar 29, 2023 | P00010 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Aug 23, 2022 | P00009 | $39.3K | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Mar 1, 2022 | P00008 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Nov 23, 2021 | P00007 | $3.6M | EO14042 - THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Aug 27, 2021 | P00006 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Mar 31, 2021 | P00005 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Feb 18, 2021 | P00004 | $2.9M | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Dec 7, 2020 | P00003 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Aug 31, 2020 | P00002 | $0 | THE PURPOSE OF THIS CONTRACT IS TO ENABLE ADVANCED PRECLINICAL DEVELOPMENT OF AN INTRANASAL RECOMBINANT AMEBIASIS VACCINE CONTAINING A LIPOSOMAL ADJUVANT FORMULATION OF CLINICAL TLR4 AND TLR7/8 LIGANDS. |
| Jul 26, 2019 | P00001 | $752.8K | IGF OT IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT. |
| Sep 19, 2018 | 0 | $2.7M | IGF:OT::IGF - ADVANCED DEVELOPMENT AND CLINICAL EVALUATION OF A SYNTHETIC INTRANASAL ENTAMOEBA HISTOLYTICA VACCINE CONTAINING ADJUVANT. |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.